---
schema_version: "secwatch.filing_event.v1"
accession: "0001651308-25-000151"
form_type: "8-K"
ticker: "ONC"
cik: "0001651308"
company_name: "BeOne Medicines Ltd."
filed_at: "2025-12-18T23:59:59+00:00"
generated_at: "2026-05-16T12:45:08.048344+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# BeOne Medicines promotes Lai Wang to President, Global Head of R&D effective Jan 1, 2026

## Summary
- Dr. Lai Wang appointed President, Global Head of R&D, overseeing R&D, business development, and alliance management.
- Promotion effective January 1, 2026; annual salary $750,000 with target bonus of 75% of base salary.
- One-time RSU equity award of $10M vesting in equal annual installments over four years.
- Dr. Wang had served as Global Head of R&D since April 2021 and joined the company in 2011.
- No family relationships or material interests in transactions with directors or officers.

## SEC filing metadata
- accession: 0001651308-25-000151
- form_type: 8-K
- ticker: ONC
- cik: 0001651308
- company_name: BeOne Medicines Ltd.
- filed_at: 2025-12-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651308/000165130825000151/0001651308-25-000151-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651308/000165130825000151/bgne-20251217.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001651308-25-000151
- JSON: https://secwatch.observer/filing/0001651308-25-000151.json
- Plain text: https://secwatch.observer/filing/0001651308-25-000151.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.